COMPLETED

Prospective Clinical Trial of HIV+ Living Donor Kidney Donation for HIV+ Recipients

Conditions

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Prospective Clinical Trial of HIV+ Living Donor Kidney Donation for HIV+ Recipients

Official Title

Prospective Clinical Trial of HIV+ Living Donor Kidney Donation for HIV+ Recipients

Quick Facts

Study Start:2017-08-01

Study Completion:2023-07-01

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:COMPLETED

Study ID

NCT03408106

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:21 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* Able to understand and provide consent * Age 21 years or older * Meets standard clinical criteria for living donation per Johns Hopkins University (JHU) Comprehensive Transplant Center Policy * Documented HIV infection (by any licensed Enzyme-linked Immunosorbent Assay (ELISA) and confirmation by Western Blot, positive HIV Ab Immunofluorescent Assay (IFA), or documented history of detectable HIV-1 RNA) * CD4+ T-cell count ≥ 500/µL for 6 months prior to donation * HIV-1 RNA below 50 copies RNA/mL (viral blips between 50-400 copies will be allowed as long as there are not consecutive measurements \>200 copies/mL)	* Two high risk alleles of APOL1 (G1 or G2 variants) * Hypertension * Diabetes * Chronic active hepatitis C (detectable HCV RNA in plasma) * Evidence of invasive opportunistic complications from HIV infection * Mentally incompetent and/or inability to provide informed consent * Other medical conditions, as determined by the provider, that would preclude donation

Inclusion Criteria

Exclusion Criteria

* Able to understand and provide consent
* Age 21 years or older
* Meets standard clinical criteria for living donation per Johns Hopkins University (JHU) Comprehensive Transplant Center Policy
* Documented HIV infection (by any licensed Enzyme-linked Immunosorbent Assay (ELISA) and confirmation by Western Blot, positive HIV Ab Immunofluorescent Assay (IFA), or documented history of detectable HIV-1 RNA)
* CD4+ T-cell count ≥ 500/µL for 6 months prior to donation
* HIV-1 RNA below 50 copies RNA/mL (viral blips between 50-400 copies will be allowed as long as there are not consecutive measurements \>200 copies/mL)

* Two high risk alleles of APOL1 (G1 or G2 variants)
* Hypertension
* Diabetes
* Chronic active hepatitis C (detectable HCV RNA in plasma)
* Evidence of invasive opportunistic complications from HIV infection
* Mentally incompetent and/or inability to provide informed consent
* Other medical conditions, as determined by the provider, that would preclude donation

Contacts and Locations

Principal Investigator

Christine Durand, MD

PRINCIPAL_INVESTIGATOR

Johns Hopkins University

Study Locations (Sites)

Northwestern University

Chicago, Illinois, 60611

United States

Johns Hopkins University

Baltimore, Maryland, 21205

United States

Collaborators and Investigators

Sponsor: Johns Hopkins University

Christine Durand, MD, PRINCIPAL_INVESTIGATOR, Johns Hopkins University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2017-08-01

Study Completion Date2023-07-01

Study Record Updates

Study Start Date2017-08-01

Study Completion Date2023-07-01

Terms related to this study

Additional Relevant MeSH Terms

HIV Infections